| Entry |
|
| Name |
Palazestrant (USAN/INN) |
| Formula |
C28H36FN3O
|
| Exact mass |
449.2842
|
| Mol weight |
449.60
|
| Structure |

|
| Class |
Antineoplastic
DG01585 Estrogen receptor antagonist
|
| Efficacy |
Antineoplastic, Estrogen receptor antagonist |
| Comment |
Treatment of breast cancer
|
| Target |
|
| Pathway |
| hsa04961 | Endocrine and other factor-regulated calcium reabsorption |
|
| Brite |
Drug groups [BR:br08330]
Antineoplastic
DG01585 Estrogen receptor antagonist
D12827 Palazestrant
Target-based classification of drugs [BR:br08310]
Nuclear receptors
Estrogen like receptors
Estrogen receptor
NR3A1 (ESR1)
D12827 Palazestrant (USAN/INN)
|
| Other DBs |
|
| LinkDB |
|
| KCF data |
ATOM 33
1 C8x C 26.1800 -17.0100
2 C8y C 26.1800 -18.4100
3 C8x C 27.3924 -19.1100
4 C8x C 28.6049 -18.4100
5 C8y C 28.6049 -17.0100
6 C8x C 27.3924 -16.3100
7 C1y C 24.9676 -19.1100
8 C8y C 23.7721 -18.4196
9 C8y C 22.5596 -19.1195
10 C1x C 22.5594 -20.5195
11 C1y C 23.7549 -21.2099
12 N1y N 24.9674 -20.5100
13 N4x N 23.4811 -17.0502
14 C8y C 22.0888 -16.9037
15 C8y C 21.5193 -18.1826
16 C8x C 21.2660 -15.7709
17 C8x C 19.8737 -15.9171
18 C8x C 19.3041 -17.1960
19 C8x C 20.1269 -18.3287
20 C1b C 26.1966 -21.2200
21 C1d C 26.1962 -22.6099
22 C1a C 23.7547 -22.6098
23 C1a C 24.7962 -22.6099
24 X F 27.5962 -22.6099
25 C1a C 26.1962 -24.0099
26 O2a O 29.8360 -16.2990
27 C1y C 31.0412 -16.9947
28 C1x C 31.4054 -18.3530
29 N1y N 32.7637 -17.9888
30 C1x C 32.3995 -16.6305
31 C1b C 33.9740 -18.6873
32 C1b C 35.1670 -17.9980
33 C1a C 36.3558 -18.6841
BOND 37
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 7 2 1 #Up
8 7 8 1
9 8 9 2
10 9 10 1
11 10 11 1
12 11 12 1
13 7 12 1
14 8 13 1
15 13 14 1
16 14 15 1
17 9 15 1
18 14 16 2
19 16 17 1
20 17 18 2
21 18 19 1
22 15 19 2
23 12 20 1
24 20 21 1
25 11 22 1 #Down
26 21 23 1
27 21 24 1
28 21 25 1
29 5 26 1
30 26 27 1
31 27 28 1
32 28 29 1
33 29 30 1
34 27 30 1
35 29 31 1
36 31 32 1
37 32 33 1
|